ストックスクリーナーアプリを入手
1.71
3.64%
0.06
アフターアワーズ：
1.70
-0.01
-0.58%
前日終値:
$1.65
開ける：
$1.65
24時間の取引高:
1.25M
Relative Volume:
0.57
時価総額：
$156.41M
収益：
-
当期純損益:
$-67.68M
株価収益率:
-1.0301
EPS:
-1.66
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
+25.74%
1か月 パフォーマンス:
+4.91%
6か月 パフォーマンス:
-36.90%
1年 パフォーマンス:
-61.66%
1日の値動き範囲:
$1.63
$1.715
1週間の範囲:
$1.26
$1.75
52週間の値動き範囲:
$0.9857
$6.26
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.71 | 150.92M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Why is Cabaletta Bio Inc. stock going upVolume Spike & Accurate Buy Signal Notifications - mustnews.co.kr
Is Cabaletta Bio Inc. stock a buy or sellWatch List & Risk Controlled Stock Alerts - mustnews.co.kr
Published on: 2025-08-15 22:30:57 - thegnnews.com
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - 富途牛牛
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Federated Hermes Inc. - MarketBeat
CABA.O Spikes Sharply—Was It a KDJ Golden Cross or Broader Biotech Rotation? - AInvest
Cabaletta Bio Surges 25.56% Amid Sector Turmoil: What's Fueling This Biotech's Rally? - AInvest
Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA) - The Globe and Mail
What makes Cabaletta Bio Inc. stock price move sharplyPrice Volume Breakout Screener - thegnnews.com
Cabaletta Bio shares fall 1.84% intraday due to lock-up agreements on stock options and warrants. - AInvest
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - Yahoo Finance
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
Are Bears Losing Grip on Cabaletta Bio Inc.Real-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Cabaletta Bio shares rise 4.41% premarket as stock options lock-up agreement ends. - AInvest
Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Wells Fargo Adjusts Price Target for Cabaletta Bio to $2.00, Reflecting a 33.33% Decrease from $3.00. - AInvest
Guggenheim lowers Cabaletta Bio stock price target to $15 on dilution - Investing.com Canada
Guggenheim lowers Cabaletta Bio stock price target to $15 on dilution By Investing.com - Investing.com South Africa
Cabaletta Bio Reports Progress in Clinical Trials - TipRanks
Jefferies lowers Cabaletta Bio stock price target to $14 from $28 - Investing.com
Cabaletta Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Cabaletta Bio (CABA) Plans $240M Mixed Securities Offering - GuruFocus
Cabaletta Bio Files $240 Million Shelf Offering - MarketScreener
Cabaletta Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis - TipRanks
Cabaletta Bio (CABA) Q2 Loss Widens 30% - The Globe and Mail
Cabaletta Bio Inc files for mixed shelf offering of up to $240 million- SEC filing - MarketScreener
Cabaletta Bio Q2 2025: RESET-Myositis trial enrollment to start in 2H25, BLA submission in 2027. - AInvest
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update | CABA Stock News - GuruFocus
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer - TipRanks
Individual investors who have a significant stake must be disappointed along with institutions after Cabaletta Bio, Inc.'s (NASDAQ:CABA) market cap dropped by US$17m - Yahoo Finance
Cabaletta Bio Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 17:06:26 - beatles.ru
How does Cabaletta Bio Inc. compare to its industry peersUnlock expert market analysis instantly - Jammu Links News
What institutional investors are buying Cabaletta Bio Inc. stockRapidly expanding wealth - Jammu Links News
How does Cabaletta Bio Inc. generate profit in a changing economyInvest smarter with actionable trading signals - Jammu Links News
What analysts say about Cabaletta Bio Inc. stockAchieve remarkable returns with smart investing - Jammu Links News
Should I hold or sell Cabaletta Bio Inc. stock in 2025Sky-high return potential - Jammu Links News
What is the dividend policy of Cabaletta Bio Inc. stockTurn market volatility into profit opportunities - Jammu Links News
What drives Cabaletta Bio Inc. stock priceUnlock powerful market trend analysis - Jammu Links News
How volatile is Cabaletta Bio Inc. stock compared to the marketConsistently exceptional gains - Jammu Links News
When is Cabaletta Bio Inc. stock expected to show significant growthBreakthrough financial growth - Jammu Links News
Cabaletta Bio Inc. Stock Analysis and ForecastGet ahead with breakthrough trading ideas - Jammu Links News
What catalysts could drive Cabaletta Bio Inc. stock higher in 2025High-performance investment picks - Jammu Links News
Is Cabaletta Bio Inc. a growth stock or a value stockMaximize returns with strategic stock selection - Jammu Links News
What is Cabaletta Bio Inc. company’s growth strategyCapitalize on fast-moving market trends - Jammu Links News
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):